FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 國際商業結算控股有限公司 （於百慕達註冊成立之有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00147 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 498,000,000,000 | HKD | | 0.001 | HKD | | 498,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 498,000,000,000 | HKD | | 0.001 | HKD | | 498,000,000 | | 2 ...

INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.147hk.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of Current Corporate Communication. 國際商業結算控股有限公 司 (Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） (S ...

（股份代號：00147） INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED 國際商業結算控股有限公 司 (Incorporated in Bermuda with limited liability) (Stock Code: 00147) （於百慕達註冊成立之有限公司） NOTIFICATION LETTER 通知信函 29 December 2025 Dear Registered Shareholder, International Business Settlement Holdings Limited (the "Company") Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's we ...

BOARD OF DIRECTORS Executive Directors Yuen Leong Chan Siu Tat Non-executive Director Liu Yu Independent Non-executive Directors Yap Yung Chen Lanran Wong Kin Ping Contents 目錄 | Corporate Information | 2 | 公司資料 | | --- | --- | --- | | Report on Review of Condensed Consolidated Financial Statements | 4 | 簡明綜合財務報表審閱報告 | | Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income | 6 | 簡明綜合損益及其他全面收益表 | | Condensed Consolidated Statement of Financial Position | 8 | 簡明綜合財務狀況表 | | Condense ...

本次XLS-103注射液获得临床试验许可，是香雪生命科学基于现有的TCR T细胞治疗核心技术和研发平 台获得的第六个和第七个关于TCR-T产品的《临床试验通知书》。 智通财经APP讯，ST香雪(300147.SZ)发布公告，公司子公司香雪生命科学技术(广东)有限公司(以下简 称"香雪生命科学")收到国家药品监督管理局签发的两份《药物临床试验批准通知书》(通知书编号分别 为：2025LP03514、 2025LP03515)，香雪生命科学的XLS-103注射液新药临床注册申请获得临床试验许 可。 ...

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The company has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronic Technology Co., Ltd., for the supply of integrated circuit (IC) chips totaling 1.61 million units, valued at approximately $19.95 million (around HKD 156 million) [1] Group 1 - The agreement is part of the company's routine business operations and aims to expand its product portfolio in the computer equipment sector [1] - The company is committed to seeking business developments that enhance long-term shareholder value [1]

Core Viewpoint - International Commercial Settlement (00147.HK) announced a computer chip sales agreement with Shenzhen Nanjiguang Electronics Technology Co., Ltd. (stock code: 300940.SZ) through its wholly-owned subsidiary Hong Kong Nanjiguang Technology Co., Ltd. on December 5, 2025 [1] Group 1 - The agreement involves the sale of computer chips [1] - The partnership is expected to enhance the technological capabilities of the involved companies [1] - The agreement signifies a strategic move in the semiconductor market [1]

Core Viewpoint - International Commercial Settlement (00147.HK) has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronics Technology Co., Ltd. (300940.SZ), for the supply of integrated circuit (IC) chips totaling 1,610,000 units, valued at approximately $19.95 million (around HKD 156 million) [1] Group 1 - The agreement is set to be executed by December 5, 2025, indicating a long-term commitment to the supply of IC chips [1] - The total contract value of approximately $19.95 million reflects the company's strategic move to expand its product portfolio in the computer equipment business [1] - The board believes that the transaction under the chip sales agreement is part of the company's routine and general business operations, aiming to capitalize on growth opportunities in the IC chip market [1]

Core Viewpoint - International Commercial Settlement (00147) has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronics Technology Co., Ltd., for the supply of 1.61 million integrated circuit (IC) chips valued at approximately $19.95 million (around HKD 156 million) [1]. Group 1 - The agreement is set to be executed on December 5, 2025, and is part of the company's routine business operations [1]. - The chip sales agreement expands the company's product portfolio in the computer equipment business [1]. - The company is committed to seeking business developments that enhance long-term shareholder value [1].